Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA4 | P22748 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152187 | 1.00 | CA12 (0.46) | CA12CA1CA2CA4CA9 | |
| SCHEMBL10104116 | 0.98 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL16914736 | 0.94 | CA12 (0.44) | CA12CA1CA2CA4CA9 | |
| SCHEMBL6152189 | 0.85 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17768307 | 0.85 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL18242953 | 0.85 | PTGS2 (0.40) | CA12CA1CA2CA4CA9 | |
| SCHEMBL16914691 | 0.83 | CA12 (0.49) | CA12CA1CA2CA4CA9 | |
| SCHEMBL25180691 | 0.82 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1842696 | 0.82 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL25180667 | 0.82 | CA12 (0.50) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414621-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2023-12-28 | — | — | US | disclosed |
| EP-3220905-A1 | COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS | Nicox S.A. (FR) | 2017-09-27 | — | — | EP | disclosed |
| CN-106999452-A | Combination of prostanoids and nitric oxide donor | 尼科斯股份有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2016079142-A1 | COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS | NICOX S.A. (FR) | 2016-05-26 | — | — | WO | disclosed |
| EP-1527045-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011421-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414621-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | PDE5A, PDE2A, PDE3A | CA12 3806/4885CA1 2685/4885CA2 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.